Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
insulin glargine + VIAject
- Development stage
- Preclinical
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
This appears to be a combination of insulin glargine (a long-acting insulin analog) and VIAject (a rapid-acting insulin). However, there is insufficient information in the provided search results about this specific combination. Insulin glargine is a long-acting synthetic insulin analog that provides a steady level of insulin over 24 hours, while VIAject (also known as Linjeta) is a rapid-acting insulin.
- Brand names
- VIAjectLantusBasaglarToujeoSemgleeRezvoglar
02
Targets
IGF-1R (Insulin-like growth factor 1 receptor)INSR (Insulin receptor)
Beyond the preview
Go deeper on insulin glargine + VIAject.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on insulin glargine + VIAject.